Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia 6Myelodysplastic Syndromes 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Anemia, Refractory, with Excess of Blasts 2Neutropenia 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hematologic Diseases 1Blast Crisis 1Anemia, Refractory 1

Interventions

Cytarabine 197Azacitidine 143Cyclophosphamide 136fludarabine phosphate 112fludarabine 97Busulfan 96venetoclax 95Mycophenolic Acid 82Whole-Body Irradiation 81Tacrolimus 78Peripheral Blood Stem Cell Transplantation 78Decitabine 62Filgrastim 56Granulocyte Colony-Stimulating Factor 54Cyclosporine 53Melphalan 52Methotrexate 51Idarubicin 51Daunorubicin 49Antilymphocyte Serum 47Clofarabine 43Etoposide 41Thiotepa 35Gemtuzumab 34Mitoxantrone 32Stem Cell Transplantation 31CPX-351 27Specimen Handling 25Radiotherapy 25thymoglobulin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Acute × lintuzumab × Clear all
NCT00528333 2015-01-07

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Seagen Inc.

Phase 2 Completed
211 enrolled
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Acute

NCT00006084 2013-12-19

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Unknown
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡